Abstract
CD99 is a surface molecule expressed on various cell types including cancer cells. Expression of CD99 on multiple myeloma is associated with CCND1-IGH fusion/t(11;14). This translocation has been reported to be a genetic hallmark of mantle cell lymphoma (MCL). MCL is characterized by overexpression of cyclin D1 and high tumor proliferation. In this study, high expression of CD99 on MCL cell lines was confirmed. Our generated anti-CD99 monoclonal antibody (mAb), termed MT99/3, exerted potent antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities against mantle B-cell lymphoma without direct cytotoxic effects. The anti-tumor activities of mAb MT99/3 were more effective in MCL than in other B-cell lymphomas. Moreover, in a mouse xenograft model using Z138 MCL cell line, treatment of mAb MT99/3 reduced tumor development and growth. Our study indicated that mAb MT99/3 is a promising immunotherapeutic candidate for mantle cell lymphoma therapy.
Similar content being viewed by others
Abbreviations
- CCND1:
-
Cyclin D1
- CD:
-
Cluster of differentiation
- FITC:
-
Fluorescein isothiocyanate
- HRP:
-
Horseradish peroxidase
- PE:
-
Phycoerythrin
References
Aubrit F, Gelin C, Pham D, Raynal B, Bernard A (1989) The biochemical characterization of E2, a T cell surface molecule involved in rosettes. Eur J Immunol 19(8):1431–1436. https://doi.org/10.1002/eji.1830190813
Ambros IM, Ambros PF, Strehl S, Kovar H, Gadner H, Salzer-Kuntschik M (1991) MIC2 is a specific marker for Ewing’s sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing’s sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer 67(7):1886–1893
Kasinrerk W, Tokrasinwit N, Moonsom S, Stockinger H (2000) CD99 monoclonal antibody induce homotypic adhesion of Jurkat cells through protein tyrosine kinase and protein kinase C-dependent pathway. Immunol Lett 71(1):33–41
Khunkaewla P, Chiampanichayakul S, Yasamut U, Pata S, Kasinrerk W (2007) Production, characterization, and functional analysis of newly established CD99 monoclonal antibodies MT99/1 and MT99/2. Hybridoma (Larchmt) 26(4):241–250. https://doi.org/10.1089/hyb.2007.0504
Hahn JH, Kim MK, Choi EY, Kim SH, Sohn HW, Ham DI, Chung DH, Kim TJ, Lee WJ, Park CK, Ree HJ, Park SH (1997) CD99 (MIC2) regulates the LFA-1/ICAM-1-mediated adhesion of lymphocytes, and its gene encodes both positive and negative regulators of cellular adhesion. J Immunol 159(5):2250–2258
Alberti I, Bernard G, Rouquette-Jazdanian AK, Pelassy C, Pourtein M, Aussel C, Bernard A (2002) CD99 isoforms expression dictates T cell functional outcomes. FASEB J 16(14):1946–1948. https://doi.org/10.1096/fj.02-0049fje
Byun HJ, Hong IK, Kim E, Jin YJ, Jeoung DI, Hahn JH, Kim YM, Park SH, Lee H (2006) A splice variant of CD99 increases motility and MMP-9 expression of human breast cancer cells through the AKT-, ERK-, and JNK-dependent AP-1 activation signaling pathways. J Biol Chem 281(46):34833–34847. https://doi.org/10.1074/jbc.M605483200
Scotlandi K, Zuntini M, Manara MC, Sciandra M, Rocchi A, Benini S, Nicoletti G, Bernard G, Nanni P, Lollini PL, Bernard A, Picci P (2007) CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity. Oncogene 26(46):6604–6618. https://doi.org/10.1038/sj.onc.1210481
Pasello M, Manara MC, Scotlandi K (2018) CD99 at the crossroads of physiology and pathology. J Cell Commun Signal 12(1):55–68. https://doi.org/10.1007/s12079-017-0445-z
Cerisano V, Aalto Y, Perdichizzi S, Bernard G, Manara MC, Benini S, Cenacchi G, Preda P, Lattanzi G, Nagy B, Knuutila S, Colombo MP, Bernard A, Picci P, Scotlandi K (2004) Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing’s sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene 23(33):5664–5674. https://doi.org/10.1038/sj.onc.1207741
Jung KC, Kim NH, Park WS, Park SH, Bae Y (2003) The CD99 signal enhances Fas-mediated apoptosis in the human leukemic cell line. Jurkat FEBS Lett 554(3):478–484
Watson RL, Buck J, Levin LR, Winger RC, Wang J, Arase H, Muller WA (2015) Endothelial CD99 signals through soluble adenylyl cyclase and PKA to regulate leukocyte transendothelial migration. J Exp Med 212(7):1021–1041. https://doi.org/10.1084/jem.20150354
Huang X, Zhou X, Wang Z, Li F, Liu F, Zhong L, Li X, Han X, Wu Z, Chen S, Zhao T (2012) CD99 triggers upregulation of miR-9-modulated PRDM1/BLIMP1 in Hodgkin/Reed-Sternberg cells and induces redifferentiation. Int J Cancer 131(4):E382-394. https://doi.org/10.1002/ijc.26503
Laopajon W, Pata S, Takheaw N, Surinkaew S, Khummuang S, Kasinrerk W (2019) Triggering of CD99 on monocytes by a specific monoclonal antibody regulates T cell activation. Cell Immunol 335:51–58. https://doi.org/10.1016/j.cellimm.2018.10.012
Waclavicek M, Majdic O, Stulnig T, Berger M, Sunder-Plassmann R, Zlabinger GJ, Baumruker T, Stockl J, Ebner C, Knapp W, Pickl WF (1998) CD99 engagement on human peripheral blood T cells results in TCR/CD3-dependent cellular activation and allows for Th1-restricted cytokine production. J Immunol 161(9):4671–4678
Bremond A, Meynet O, Mahiddine K, Coito S, Tichet M, Scotlandi K, Breittmayer JP, Gounon P, Gleeson PA, Bernard A, Bernard G (2009) Regulation of HLA class I surface expression requires CD99 and p230/golgin-245 interaction. Blood 113(2):347–357. https://doi.org/10.1182/blood-2008-02-137745
Sohn HW, Shin YK, Lee IS, Bae YM, Suh YH, Kim MK, Kim TJ, Jung KC, Park WS, Park CS, Chung DH, Ahn K, Kim IS, Ko YH, Bang YJ, Kim CW, Park SH (2001) CD99 regulates the transport of MHC class I molecules from the Golgi complex to the cell surface. J Immunol 166(2):787–794
Manara MC, Bernard G, Lollini PL, Nanni P, Zuntini M, Landuzzi L, Benini S, Lattanzi G, Sciandra M, Serra M, Colombo MP, Bernard A, Picci P, Scotlandi K (2006) CD99 acts as an oncosuppressor in osteosarcoma. Mol Biol Cell 17(4):1910–1921. https://doi.org/10.1091/mbc.e05-10-0971
Manara MC, Pasello M, Scotlandi K (2018) CD99: a cell surface protein with an oncojanus role in tumors. Genes (Basel). https://doi.org/10.3390/genes9030159
Scotlandi K, Perdichizzi S, Bernard G, Nicoletti G, Nanni P, Lollini PL, Curti A, Manara MC, Benini S, Bernard A, Picci P (2006) Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing’s sarcoma. Eur J Cancer 42(1):91–96. https://doi.org/10.1016/j.ejca.2005.09.015
Pettersen RD, Bernard G, Olafsen MK, Pourtein M, Lie SO (2001) CD99 signals caspase-independent T cell death. J Immunol 166(8):4931–4942
Husak Z, Printz D, Schumich A, Potschger U, Dworzak MN (2010) Death induction by CD99 ligation in TEL/AML1-positive acute lymphoblastic leukemia and normal B cell precursors. J Leukoc Biol 88(2):405–412. https://doi.org/10.1189/jlb.0210097
Chung SS, Eng WS, Hu W, Khalaj M, Garrett-Bakelman FE, Tavakkoli M, Levine RL, Carroll M, Klimek VM, Melnick AM, Park CY (2017) CD99 is a therapeutic target on disease stem cells in myeloid malignancies. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aaj2025
Lee H, Park HJ, Park EH, Ju HY, Oh CM, Kong HJ, Jung KW, Park BK, Lee E, Eom HS, Won YJ (2018) Nationwide statistical analysis of lymphoid malignancies in Korea. Cancer Res Treat 50(1):222–238. https://doi.org/10.4143/crt.2017.093
Pileri SA, Falini B (2009) Mantle cell lymphoma. Haematologica 94(11):1488–1492. https://doi.org/10.3324/haematol.2009.013359
Arora M, Gowda S, Tuscano J (2016) A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma. Ther Adv Hematol 7(4):209–221. https://doi.org/10.1177/2040620716652861
Jares P, Colomer D, Campo E (2007) Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 7(10):750–762. https://doi.org/10.1038/nrc2230
Dreyling M, Amador V, Callanan M, Jerkeman M, Le Gouill S, Pott C, Rule S, Zaja F, European Mantle Cell Lymphoma N (2015) Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma 56(4):866–876. https://doi.org/10.3109/10428194.2014.940584
Chen Y, Wang M, Romaguera J (2014) Current regimens and novel agents for mantle cell lymphoma. Br J Haematol 167(1):3–18. https://doi.org/10.1111/bjh.13000
Gao Q, Yellapantula V, Fenelus M, Pichardo J, Wang L, Landgren O, Dogan A, Roshal M (2018) Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms. Mod Pathol 31(6):881–889. https://doi.org/10.1038/s41379-018-0011-0
Pokrass MJ, Liu MF, Lindorfer MA, Taylor RP (2013) Activation of complement by monoclonal antibodies that target cell-associated beta(2)-microglobulin: implications for cancer immunotherapy. Mol Immunol 56(4):549–560. https://doi.org/10.1016/j.molimm.2013.05.242
Dworzak MN, Fritsch G, Buchinger P, Fleischer C, Printz D, Zellner A, Schollhammer A, Steiner G, Ambros PF, Gadner H (1994) Flow cytometric assessment of human MIC2 expression in bone marrow, thymus, and peripheral blood. Blood 83(2):415–425
Lee SP, Park S, Park J, Hong J, Ko YH (2011) Clinicopathologic characteristics of CD99-positive diffuse large B-cell lymphoma. Acta Haematol 125(3):167–174. https://doi.org/10.1159/000322551
Bernard G, Breittmayer JP, de Matteis M, Trampont P, Hofman P, Senik A, Bernard A (1997) Apoptosis of immature thymocytes mediated by E2/CD99. J Immunol 158(6):2543–2550
Bakema JE, van Egmond M (2014) Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer. Curr Top Microbiol Immunol 382:373–392. https://doi.org/10.1007/978-3-319-07911-0_17
Redman JM, Hill EM, AlDeghaither D, Weiner LM (2015) Mechanisms of action of therapeutic antibodies for cancer. Mol Immunol 67(2 Pt A):28–45. https://doi.org/10.1016/j.molimm.2015.04.002
Lo Nigro C, Macagno M, Sangiolo D, Bertolaccini L, Aglietta M, Merlano MC (2019) NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives. Ann Transl Med 7(5):105. https://doi.org/10.21037/atm.2019.01.42
Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, Sotto JJ, Leroux D, Bensa JC, Plumas J (2003) In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 101(3):949–954. https://doi.org/10.1182/blood-2002-02-0469
Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, Groen RW, van Duin M, Sonneveld P, Minnema MC, Zweegman S, Chiu C, Bloem AC, Mutis T, Lokhorst HM, Sasser AK, van de Donk NW (2016) CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood 128(7):959–970. https://doi.org/10.1182/blood-2016-03-703439
Bannerji R, Kitada S, Flinn IW, Pearson M, Young D, Reed JC, Byrd JC (2003) Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol 21(8):1466–1471. https://doi.org/10.1200/JCO.2003.06.012
Kato Y, Kunita A, Fukayama M, Abe S, Nishioka Y, Uchida H, Tahara H, Yamada S, Yanaka M, Nakamura T, Saidoh N, Yoshida K, Fujii Y, Honma R, Takagi M, Ogasawara S, Murata T, Kaneko MK (2017) Antiglycopeptide mouse monoclonal antibody LpMab-21 exerts antitumor activity against human podoplanin through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Monoclon Antib Immunodiagn Immunother 36(1):20–24. https://doi.org/10.1089/mab.2016.0045
Takei J, Ohishi T, Kaneko MK, Harada H, Kawada M, Kato Y (2020) A defucosylated anti-PD-L1 monoclonal antibody 13-mG2a-f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma. Biochem Biophys Rep 24:100801. https://doi.org/10.1016/j.bbrep.2020.100801
Watanabe M, Ohishi T, Kuzuoka M, Nudelman ED, Stroud MR, Kubota T, Kodairo S, Abe O, Hirohashi S, Shimosato Y et al (1991) In vitro and in vivo antitumor effects of murine monoclonal antibody NCC-ST-421 reacting with dimeric Le(a) (Le(a)/Le(a)) epitope. Cancer Res 51(8):2199–2204
Guhad FA, Jensen HE, Hau J (2000) Complement activation in SCID and nude mice is related to severity of tissue inflammation in the Candida mastitis model. FEMS Microbiol Lett 192(1):27–31. https://doi.org/10.1111/j.1574-6968.2000.tb09354.x
Dhandapani M, Goldman A (2017) Preclinical cancer models and biomarkers for drug development: new technologies and emerging tools. J Mol Biomark Diagn. https://doi.org/10.4172/2155-9929.1000356
Gengenbacher N, Singhal M, Augustin HG (2017) Preclinical mouse solid tumour models: status quo, challenges and perspectives. Nat Rev Cancer 17(12):751–765. https://doi.org/10.1038/nrc.2017.92
Feng L, Wang W, Yao HP, Zhou J, Zhang R, Wang MH (2015) Human tumor xenografts in mouse as a model for evaluating therapeutic efficacy of monoclonal antibodies or antibody-drug conjugate targeting receptor tyrosine kinases. Methods Mol Biol 1233:151–159. https://doi.org/10.1007/978-1-4939-1789-1_14
Schenkel AR, Mamdouh Z, Chen X, Liebman RM, Muller WA (2002) CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat Immunol 3(2):143–150. https://doi.org/10.1038/ni749
Choi G, Roh J, Park CS (2016) CD99 is strongly expressed in basal cells of the normal adult epidermis and some subpopulations of appendages: comparison with developing fetal skin. J Pathol Transl Med 50(5):361–368. https://doi.org/10.4132/jptm.2016.06.19
Funding
This work was supported by the Distinguished Research Professor Grant (NRCT808/2563) of the National Research Council of Thailand, Chiang Mai University Center of Excellence Project and Japan Student Services Organization (JASSO) scholarship (Grant no. UTB1717401001).
Author information
Authors and Affiliations
Contributions
NT conceived the study, designed and carried out experiments, analyzed data and drafted the manuscript. GS performed ADCC assay of IL-2 activated splenocytes and participated in in vivo experiments. RK participated in in vivo experiments. WK and SO conceived the study, and were involved in the experimental design, interpretation of results and editing the manuscript. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval and ethical standards
Mice were bred and cared for in the animal research facility according to institutional guidelines. All experimental procedures in this study were approved by the Institutional Animal Care and Use Committee at Kumamoto University, Japan.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Takheaw, N., Sittithumcharee, G., Kariya, R. et al. Anti-human CD99 antibody exerts potent antitumor effects in mantle cell lymphoma. Cancer Immunol Immunother 70, 1557–1567 (2021). https://doi.org/10.1007/s00262-020-02789-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-020-02789-0